Here, in this section, we discuss potential combination therapy with nuclear factor erythroid factor 2 related factor 2 (Nrf2) activators and immunosuppressive medication to magnify the beneficial effects of β-cell proliferation agents in the treatment of T1DM and T2DM. This evidence concerns the gene NFE2L2 and type 1 diabetes mellitus.